CONTACTS
SUBJECTS
VA Prescribe Atorvastin 10 MG Trial 4 Weeks Evaluate Side Effects In
6003 -
6003 - ..
6004 - Summary/Objective
6005 -
600501 - Follow up
600502 -
600503 - Follow up ref SDS 68 0001, ref SDS 31 0000. ref SDS 65 0000.
600504 -
600505 -
600506 -
600507 -
600508 -
600509 -
600510 -
600512 - ..
6006 -
6007 -
6008 - Background
6009 -
6010 -
601001 - Lab on 131015, showing cholesterol remained high, 131015 0724,
601002 - ref SDS 38 BE6O, conflict with increased exercise and weight loss,
601003 - discussed in the letter to the medical team yesterday on 131016 1632.
601004 - ref SDS 39 IW57
601006 - ..
601007 - On 131017 1000 VA medical chart Progress Notes assessment report
601008 - patient status CAD stable, asymptomatic. hyperlipidemia not
601009 - controlled. ref SDS 40 T24N
601011 - ..
601012 - On 131017 1000 Doctor Egan proposed referring patient for clinical
601013 - trial to reduce cholesterol with new "targeted" drugs. ref SDS 40 179N
601015 - ..
601016 - On 131017 1000 VA medical chart Progress Notes assessment report
601017 - patient status hyperlipidemia not controlled, ref SDS 40 PSXT; Doctor
601018 - Egan makes referral to SF VA Medical Center for consult on
601019 - participation clinical trials, ref SDS 40 EU9F, with experimental
601020 - agents such as AMG 145 and REGN 727 to resolve multiple statin
601021 - intolerances. ref SDS 40 CN4H
601023 - ..
601024 - On 131103 received letter from VA SF Medical Center scheduling meeting
601025 - on 131121 1000, to consider clinical trial for lowering cholesteral.
601026 - ref SDS 42 YT4N
601028 - ..
601029 - On 131112 New York Times published several articles reporting that the
601030 - day before on 131113, American Heart Association published new
601031 - guidelines for treating CAD patients that expand use of statin
601032 - medication regardless of cholesterol levels, ref SDS 43 0001, and
601033 - further raise the LDL 70 to LDL 190, as a target for cardiovascular
601034 - risk. ref SDS 43 CW6H
601036 - ..
601037 - On 131114 New York Times published several articles reporting that the
601038 - day before on 131113, American Heart Association published new
601039 - guidelines for treating CAD patients. ref SDS 44 SH6G
601041 - ..
601042 - On 131121 1604 meeting with Doctor Alba at San Francisco Medical
601043 - Center - prescribed Atorvastatin 20 mg 4-week trial and evaluate
601044 - adding Zetia 10 mg, schedule follow up on 131219 0930. ref SDS 45 6H6K
601046 - ..
601047 - On 131121 1604 in another record later today, VA prescription RX #
601048 - 5674471 for Atorvastatin 20 mg has been ordered. ref SDS 46 GH5M
601050 - ..
601051 - On 131125 0005 letter from Karen reports VA work plan to take statin
601052 - drug low dose Atvorstatin 10 mg for 4 weeks, then add Zetia 10 mg in
601053 - clinical trial for lowering cholesterol. ref SDS 48 V154
601055 - ..
601056 - On 131125 0005 research seems to indicate this clincial trial of low
601057 - dose Atorvasatatin 10 mg with Zeitia 10 mg has lowered cholesterol LDL
601058 - 70.
601060 - ..
601061 - On 131205 1448 received new prescription for Atvorstatin 20 mg,
601062 - ordered by Doctor Alba today for 4-week trial to assess side effects
601063 - for adding 2nd drug, Zetia 10 mg to lower LDL 249. ref SDS 49 GH5M
601065 - ..
601066 - On 131216 0028 letter to Doctor Alba submit agenda for meeting at VA
601067 - SFMC on 131219. ref SDS 50 HY6O
601069 - ..
601070 - On 131219 0930 meeting Doctor Alba at San Francisco VA Medical Center
601071 - ordered Ezedimibe 10 mg prescription for adding to Atorvastatin, and
601072 - ordered blood test to evaluate changes in lipid profile. 131219 0930,
601073 - ref SDS 51 NJ6G
601075 - ..
601076 - On 131230 1450, received Ezetimibe in US mail, ref SDS 52 5N3O,
601077 - ordered by Doctor Alba on 131219, 131219 0930, ref SDS 51 6H6K; begin
601078 - trial to manage cholesterol with Atorvastatin 10 mg and Ezetimibe 10
601079 - mg, planned during meeting at VA on 131121 0930. ref SDS 45 6H6K
601081 - ..
601082 - On 140114 0845 letter to Diana request Progress Notes meeting 131219,
601083 - ref SDS 53 HY6O, and ask about expanding scope pending lab to include
601084 - LDL-P. ref SDS 53 2140
601086 - ..
601087 - On 140115 1842 letter Diana will look for Progress Notes meeting
601088 - 131219, ref SDS 54 HY6O; investigating prospects for ordering lab test
601089 - LDL-P, ref SDS 54 CE80; VA claims patient cholesterol and LDL are above
601090 - target. ref SDS 54 CE91 VA further claims testing LDL-P not effective
601091 - in this case because LDL-C is not optimal. ref SDS 54 FF4H
601093 - ..
601094 - On 140116 0814 letter thanks Doctor Alba for investigting to find
601095 - Progress Notes for meeting at VA on 131219. ref SDS 55 HY6O Cite
601096 - research indicating patient with discordant LDL-C high and LDL-P low,
601097 - shown in patient lab on 131015, constitutes least risk for
601098 - arterialsclorosis disorder, CVD, mycardial infarction. ref SDS 55 735Y
601100 - ..
601101 - On 140128 1327 letter asks again about Progress Notes meeting 131219,
601102 - ref SDS 56 HY6O; report hiking 11 miles per day continued, weight hit
601103 - 165, ref SDS 56 TZ8U; ask where to get lab at VA Martinez, in San
601104 - Francisco, or at UCSF. ref SDS 56 TZ96 No side effects from
601105 - Atorvastatin and Ezetimibe. ref SDS 56 TZ99
601107 - ..
601108 - On 140131 0815 have not received instructions from VA on getting lab
601109 - to test LDL-P, so ordered test. ref SDS 57 OO5G lab blood draw at
601110 - Labcorp in Walnut Creek on Ygnacio Valley Road. ref SDS 57 NT6T
601112 - ..
601113 - On 140201 1159 obtained blood draw for Lipid NMR test at Labcor on
601114 - Health Testing Centers order # 27716, ref SDS 58 KQ4L, showing
601115 - "concordance" LDL-P 861, LDL-C 81, HDL 61, TG 68, LDL (pattern A) size
601116 - = large bouyant protective. ref SDS 58 IM9N
601118 - ..
601119 - On 140203 1147 since have not received instructions from VA, obtained
601120 - blood draw at VA in Martinez to cross check Labcorp blood test. 140203
601121 - 1147, ref SDS 59 KK9M, showing LDL-C 93, HDL 58, TG 47, ref SDS 59
601122 - IM9N, indicating "concordance" LDL-P 626, LDL (pattern A) size = large
601123 - bouyant protective. ref SDS 59 QV5G
601125 - ..
601126 - On 140204 1236 letter from VA today, notifies that Progress Notes for
601127 - meeting on 131219, have been posted and are available for customer to
601128 - receive from ROI department. ref SDS 61 HY6O Cause for 6-weeks delay
601129 - issuing Progress Notes not clear in the record. ref SDS 61 V44F VA
601130 - Progress Notes for meeting on 131219, are comprehensive and helpful.
601131 - ref SDS 61 MR3G Progress Notes have many minor grammatical errors
601132 - likely due to limited time, ref SDS 61 MZ5H, VA does not support NMR
601133 - lipid tests to determine LDL-P and discordance with LDL-C; patient can
601134 - obtain test from another lab. ref SDS 61 CE80 VA letter today
601135 - maintains discordance with low LDL-P and high LDL-C is "unhealthy" -
601136 - submits no evidence from medical literature supporting this
601137 - proposition, nor to address literature submitted to the VA stating
601138 - discordance is the healthiest condition for CVD patients. ref SDS 61
601139 - 6U4L VA concurs that lowering weight toward BMI standards aids
601140 - resolving hyperlipidemia. ref SDS 61 8N9H VA maintains lifestyle
601141 - through exercise and diet to control weight and hyperlipidemia require
601142 - support taking statin medications, e.g., Atorvastatin and Ezetimibe.
601143 - ref SDS 61 GT5F VA letter today says patient mis-reads literature on
601144 - discordance between LDL-P and LDL-C, and proposes discussions to
601145 - clarify this matter during meeting scheduled on 140213. ref SDS 61 HU5M
601146 - VA prefers patient get labs drawn at San Francisco VA Medical Center.
601147 - ref SDS 61 PT3M
601149 - ..
601150 - On 140213 0830 meeting VA San Francisco, ref SDS 64 195I, report good
601151 - progress lowering risks of recurrant CVD based on concordant low LDL-P
601152 - 861 with low LDL-C 81. shown by lab NMR lipid panal. ref SDS 64 TB6J
601153 - Medical team excellent results collaborating doctor/patient
601154 - partnership. ref SDS 64 1L7M Atorvastatin 40 mg started 131121, and
601155 - then changed to Atorvastatin 10 mg with Ezetimibe 10 mg started
601156 - 131230. ref SDS 64 IE7F No side effects taking medication past 6
601157 - weeks. ref SDS 64 333L Objectives and ramifications of discordance
601158 - between LDL-P and LDL-C discussed. ref SDS 64 WM8J Regression of
601159 - atherosclerosis plaque can be assessed with CT and IVUS modalities to
601160 - evaluate recovery from prior acute condition that required surgery in
601161 - 2009. ref SDS 64 JZ4O Will continue medication, diet, exercise and
601162 - weight loss protocols, and test lipid panal again in 3 months on
601163 - 140519 0800. ref SDS 64 8X5O Did not discuss today elevated potasium
601164 - and bilirubin. ref SDS 64 GT7G
601166 - ..
601167 - On 140226 1332 letter to VA transmits notes of meeting on 140213.
601168 - ref SDS 65 HY6O Report possible cold symptoms side effects taking
601169 - Atorvastatin with Ezetimibe. ref SDS 65 JY8K Request consideration
601170 - order CT radiology assess regression atherosclerosis. ref SDS 65 JR99
601171 - Request Progress Notes meeting on 140213. ref SDS 65 JY4M
601173 - ..
601174 - On 140303 1644 letter to VA reports recovery from symptoms of cold,
601175 - which may indicate this was not caused by prescribed medication side
601176 - effects taking Atorvastatin and Ezetimibe. ref SDS 68 HY6O Letter
601177 - requests Progress Notes for meeting a few weeks ago at Medical Center
601178 - in San Francisco. ref SDS 68 E788
601179 -
601180 -
601181 -
601183 - ..
6012 -
6013 -
6014 - Progress
6015 -
601501 - Cold Symptoms Subside Evidence Not Caused Atorvastatin Ezetimibe
601502 - Progress Notes Request for Meeting San Francisco VA Medical Center
601503 -
601504 - Follow up ref SDS 31 HY6O, ref SDS 68 HY6O.
601505 -
601506 - Received letter from San Francisco VA Medical Center saying...
601507 -
601508 - 1. Subject: Re: Meeting 13 Feb Progress Notes
601509 - Date: 2014-03-05 09:27
601516 - ..
601517 - 2. I'm glad symptoms have improved.
601519 - ..
601520 - Responds to letter notifying of severe symptoms of possible side
601521 - effects taking Atorvastatin and Ezetimibe, reported to VA on 140226
601522 - 1332, ref SDS 65 JY8K, and VA was notified symptoms subsided
601523 - indicating less likely caused by side effects taking medications,
601524 - reported on 140303 1644. ref SDS 68 HY6O
601526 - ..
601527 - VA letter continues...
601528 -
601529 - 3. The progress note should be in this week.
601531 - ..
601532 - Diana responds to the letter notifying symptoms of illness, reported
601533 - on 140226 1332, ref SDS 65 JY8K, have subsided, reported on 140303
601534 - 1644, ref SDS 68 HY6O, and further asking about getting Progress Notes
601535 - for meeting at VA on 140213. ref SDS 68 E788
601536 -
601537 - [...below on 140305 1117 at 1330 letter asks VA to transmit
601538 - Progress Notes using electronic correspondence that avoids
601539 - incuring time and expense driving to VA for obtaining the
601540 - record. ref SDS 31 WW6G
601542 - ..
601543 - [On 140307 1509 letter asks about Progress Notes.
601544 - ref SDS 69 5X69
601545 -
601548 -
601549 -
601551 - ..
6016 -
6017 -
6018 - 1330
6019 -
601901 - Sent letter to VA saying...
601902 -
601903 -
601904 - 1. Subject: Re: Meeting 13 Feb Progress Notes
601905 - Date: 2014-03-05 13:36
601910 - ..
601911 - 2. Thanks for your letter today, shown below. Please attach
601912 - Progress Notes to return email, so I don't have to drive back
601913 - again to VA in Martinez.
601915 - ..
601916 - Responds to VA letter earlier today saying Progress Notes for meeting
601917 - at VA on 140213, will be published later this week, per above.
601918 - ref SDS 31 GO9N
601919 -
601920 - [On 140307 1509 letter asks about Progress Notes.
601921 - ref SDS 69 5X69
601923 - ..
601924 - Letter to VA continues...
601925 -
601926 - 3. Have you considered CT and/or IVUS to evaluate regression of
601927 - atherosclerosis, as set out in notes on 140213 (line 601800.
601928 - ref SDS 63 GT6J
601930 - ..
601931 - This follows up letter to VA on 140226 1332, ref SDS 65 JR99
601932 - transmitting and referencing the record discussing regression of
601933 - atherosclerosis lesions shown in the record for the meeting at the VA
601934 - on 140213 0830. ref SDS 63 JZ4O
601935 -
601938 -
601939 -
601940 -
601941 -
601942 -
601943 -
601944 -
601945 -
601946 -
601947 -
601948 -
601949 -
6020 -